Standout Papers

The spike protein of SARS-CoV — a target for vaccine and therapeutic deve... 2004 2026 2011 2018 1.1k
  1. The spike protein of SARS-CoV — a target for vaccine and therapeutic development (2009)
    Lanying Du, Yuxian He et al. Nature Reviews Microbiology
  2. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine (2020)
    Wanbo Tai, Lei He et al. Cellular and Molecular Immunology
  3. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion (2020)
    Shuai Xia, Meiqin Liu et al. Cell Research
  4. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody (2020)
    Xiaolong Tian, Cheng Li et al. Emerging Microbes & Infections
  5. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS‐CoV) in SARS patients: implications for pathogenesis and virus transmission pathways (2004)
    Yanqing Ding, Li He et al. The Journal of Pathology
  6. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses (2020)
    Shibo Jiang, Christopher D. Hillyer et al. Trends in Immunology
  7. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein (2020)
    Shuai Xia, Yun Zhu et al. Cellular and Molecular Immunology
  8. Recent advances in the detection of respiratory virus infection in humans (2020)
    Naru Zhang, Lili Wang et al. Journal of Medical Virology
  9. AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells (2021)
    Shuai Wang, Zongyang Qiu et al. Cell Research
  10. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor (2014)
    Lu Lu, Qi Liu et al. Nature Communications
  11. Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy (2021)
    Qianqian Zhang, Rong Xiang et al. Signal Transduction and Targeted Therapy
  12. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses (2022)
    Yanjia Chen, Xiaoyu Zhao et al. Nature reviews. Immunology

Immediate Impact

8 by Nobel laureates 55 from Science/Nature 243 standout
Sub-graph 1 of 14

Citing Papers

Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants
2024 Standout
Angiotensin-converting enzyme 2—at the heart of the COVID-19 pandemic
2023 Standout
74 intermediate papers

Works of Shibo Jiang being referenced

Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines
2020
Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS‐CoV) in SARS patients: implications for pathogenesis and virus transmission pathways
2004 Standout
and 47 more

Author Peers

Author Last Decade Papers Cites
Shibo Jiang 19134 4458 4214 6770 493 27.9k
Stefan Pöhlmann 20706 2341 3842 5661 226 29.9k
Michael Farzan 15381 6462 4330 7097 177 29.7k
Barney S. Graham 15203 3695 13564 5780 357 30.1k
Christian Drosten 38763 1156 6260 7281 412 51.4k
Alimuddin Zumla 21169 1266 12525 7383 615 35.6k
Linqi Zhang 10705 7041 3037 3434 225 17.8k
Pei‐Yong Shi 14932 2658 2887 4632 374 24.2k
Kuldeep Dhama 8156 719 2882 5095 889 26.2k
Shuwen Liu 6195 1648 2006 5495 509 16.5k
Alexander E. Gorbalenya 15546 755 2614 6497 181 26.7k

All Works

Loading papers...

Rankless by CCL
2026